Awakn Life Sciences Announces Closing of Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further to its press release dated April 3, 2024, it has closed a first tranche (the "First Tranche") of its previously announced non-brokered private placement (the...
2024-04-17 7:30 AM EDT
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
Toronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the launch of an additional Licensing Partnership agreement in North America. The agreement is with Rivus Wellness and Research Institute ("Rivus"), based in Oklahoma City. This is the...
2024-04-03 7:30 AM EDT
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange
Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that it has received approval to have the common shares ("Common Shares") of the Company listed on the Canadian Securities Exchange (the "CSE") under the symbol "AWKN" at the opening of...
2024-02-12 7:30 AM EST
Awakn Life Sciences Announces Conditional Approval of CSE Listing
Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce, further to its press release dated November 10, 2023, that it has made an application and received conditional approval to list its common shares on the Canadian Securities Exchange (the...
2024-02-05 7:30 AM EST
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that it has successfully completed an investigative study to establish the dissociative effect of a proprietary and patent pending S-ketamine formulation, administered sublingually via an...
2024-01-24 7:30 AM EST
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS
Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents Filed in US and Key International MarketsToronto, Ontario--(Newsfile Corp. - December 20, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing Medication-Assisted Treatments to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has signed a global licensing agreement with LTS Lohmann Therapie-Systeme AG...
2023-12-20 7:30 AM EST
Awakn Life Sciences Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), shares a corporate update on recent progress. Awakn also announces the closing of the fourth tranche of its previously announced private placement.Key recent corporate activity: Awakn received regulatory and ethical approval for...
2023-12-15 7:30 AM EST
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001
Toronto, Ontario--(Newsfile Corp. - November 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has received clinical trial authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and ethical approval from the Health Research Authority in the UK for a phase III clinical trial for its...
2023-11-15 7:30 AM EST
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements
Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has received a notice (the "Notice") from Cboe Canada ("Cboe") indicating that Awakn is not in compliance with Section 3.01(3) of Cboe's Listing Manual. Awakn has 90 days to address the non-compliance.The...
2023-11-10 5:00 PM EST
Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - October 31, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has engaged Orphan Insight Ltd ("Orphan Insight") to develop and advance market access, pricing, and reimbursement for Awakn's lead program AWKN-P001. AWKN-P001 targets Severe Alcohol Use Disorder (SAUD), the most...
2023-10-31 7:30 AM EDT
Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study
Toronto, Ontario--(Newsfile Corp. - October 4, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces it has completed a feasibility study for its proprietary formulation of MDMA using Catalent's Zydis® orally disintegrating tablet (ODT) technology. The study, which was initiated in February 2023, evaluated a...
2023-10-04 8:30 AM EDT
Awakn Life Sciences Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - September 14, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), shares a corporate update on recent progress. Awakn also announces the closing of the third tranche of its previously announced private placement.Key recent corporate activity: Healthcare services exit completed and burn...
2023-09-14 7:30 AM EDT
Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001
Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has submitted the Clinical Trial Application (CTA) for a phase III trial for its lead program AWKN-P001 for the treatment of Severe Alcohol Use Disorder (SAUD). SAUD, the most acute type of alcohol use disorder, affects...
2023-09-06 7:30 AM EDT
Awakn Life Sciences Completes Sale of Awakn Clinics In Norway
Toronto, Ontario--(Newsfile Corp. - August 1, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the sale of its clinics businesses in Norway, comprising of Awakn Clinics Oslo and Awakn Clinics Trondheim. The clinics have been purchased in a management buyout.Today's announcement marks the...
2023-08-01 7:30 AM EDT
Awakn Life Sciences Completes Sale of Awakn Clinics London
Toronto, Ontario--(Newsfile Corp. - July 5, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the sale of Awakn London Limited., Awakn's subsidiary that owns and operates its healthcare clinic in London, United Kingdom ("UK") trading as Awakn Clinics London. The subsidiary has been purchased by...
2023-07-05 7:30 AM EDT
Awakn Life Sciences Announces Results of Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 27, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting") held earlier today.All matters presented for approval at the Meeting were duly authorized and approved, as...
2023-06-27 5:00 PM EDT
Awakn Life Sciences to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC
Toronto, Ontario--(Newsfile Corp. - June 19, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that Awakn CEO, Anthony Tennyson has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Thursday, June 22nd at 9:00 A.M. ET The...
2023-06-19 7:30 AM EDT
Awakn Life Sciences Announces Closing of the Second Tranche and Upsizing of Previously Announced Private Placement
Toronto, Ontario--(Newsfile Corp. - June 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce the closing of the second tranche and upsizing of its previously announced non-brokered private placement financing. On April 26th, 2023, Awakn announced a non-brokered private placement financing for...
2023-06-15 7:30 AM EDT
Awakn Life Sciences to Focus Solely on Research and Development of Therapeutics Targeting Addiction
Term Sheet Signed to License Healthcare Intellectual Property to UK Healthcare Consortium Exclusively in the UK MarketStrategic Review of Norwegian Healthcare Clinics Business Unit InitiatedToronto, Ontario--(Newsfile Corp. - June 9, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn") a biotechnology company developing therapeutics targeting addiction, with a near term focus on Alcohol Use Disorder, announces today its intention to exit healthcare services to...
2023-06-09 12:00 PM EDT
Awakn Life Sciences Reports Q4 2023 and Annual Results
Toronto, Ontario--(Newsfile Corp. - April 28, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today it is reporting its financial results and business highlights for the three and twelve months ended January 31, 2023. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars,...
2023-04-28 7:30 AM EDT